TO THE EDITOR
=============

Accumulating evidence suggests that patients with schizophrenia exhibit nonpsychotic, nonspecific prodromal symptoms for several years before the onset of frank psychosis. A meta-analysis demonstrated that cognitive impairment is a common feature of the prodromal state of psychosis.[@b1-cpn-13-328] Accordingly, interest in the potential benefit of early intervention in psychosis is increasing.[@b2-cpn-13-328]--[@b5-cpn-13-328]

We read the recent article by Kantrowitz *et al*.,[@b6-cpn-13-328] concerning the efficacy of [d]{.smallcaps}-serine (an endogenous co-agonist at the *N*-methyl-D-aspartate receptor; NMDAR) on negative symptoms in individuals at clinical high risk of schizophrenia, with great interest. In a double-blind, placebo-controlled trial, these authors compared [d]{.smallcaps}-serine (n=20, 60 mg/kg) and placebo (n=24) for 16 weeks. The primary endpoint was scores on the negative subscale of the Scale of Prodromal Symptoms (SOPS). [d]{.smallcaps}-Serine induced a significant (35.7%) improvement in negative symptoms compared to placebo, although the number of conversions (one in the [d]{.smallcaps}-serine group and two in the placebo group) was too small for statistical analysis, in part due to the short duration of treatment. Nevertheless, these pilot data suggest that [d]{.smallcaps}-serine is an effective treatment of prodromal schizophrenia symptoms, despite the small sample size.[@b6-cpn-13-328]

Previously, we reported that serum [d]{.smallcaps}-serine levels in patients with schizophrenia were lower compared to control subjects, whereas serum [l]{.smallcaps}-serine levels were higher in patients than in controls.[@b7-cpn-13-328],[@b8-cpn-13-328] Furthermore, we reported a reduced ratio of [d]{.smallcaps}-serine to total serine ([dl]{.smallcaps}-serine) in the cerebrospinal fluid of first-episode and drug naïve schizophrenia patients, indicating decreased NMDAR neurotransmission in the brain in early phase patients.[@b9-cpn-13-328] Combined, these findings suggest that disturbed NMDAR neurotransmission, due to decreased [d]{.smallcaps}-serine levels, plays a causative role in the pathogenesis of schizophrenia.[@b2-cpn-13-328] In the brain, [d]{.smallcaps}-serine is synthesized from [l]{.smallcaps}-serine by serine racemase (SRR). A recent genome-wide association study confirmed the association between *SRR* and schizophrenia.[@b10-cpn-13-328] Furthermore, we reported that [d]{.smallcaps}-serine supplementation at between 5 and 10 weeks could prevent schizophrenia-like behavioral abnormalities in adult mice (11 weeks old) after neonatal disruption of SRR, suggesting that early intervention with [d]{.smallcaps}-serine prevents the onset of psychosis in adults.[@b11-cpn-13-328] Finally, glycine, another NMDAR co-agonist, was associated with a 10--15% reduction in negative SOPS symptoms in high-risk subjects.[@b12-cpn-13-328]

In conclusion, given the role of NMDAR hypofunction in prodromal symptoms (e.g., cognitive impairment) and early stage schizophrenia,[@b2-cpn-13-328] NMDAR modulators, including [d]{.smallcaps}-serine, glycine, [d]{.smallcaps}-alanine, and sarcosine, may be effective early intervention for psychosis because they all occur naturally in humans.
